Viking Therapeutics (VKTX) Earnings Analysis
Viking Therapeutics (VKTX) next reports earnings on 2026-07-29, consensus EPS -1.21 USD. Last quarter (2026-04-29) it missed with EPS -1.37 USD vs -1.01 USD est (-35.6%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -9.01.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does VKTX next report earnings?
| Next earnings date | 2026-07-29 |
|---|---|
| Consensus EPS estimate | -1.21 USD |
| Revenue estimate | n/a |
VKTX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-29 | -1.37 USD | -1.01 USD | -35.6% | Miss |
| 2025-10-22 | -0.81 USD | -0.7 USD | -15.7% | Miss |
| 2025-07-23 | -0.58 USD | -0.44 USD | -31.8% | Miss |
| 2025-02-05 | -0.32 USD | -0.28 USD | -14.3% | Miss |
| 2024-10-23 | -0.22 USD | -0.24 USD | +8.3% | Beat |
| 2024-07-24 | -0.2 USD | -0.26 USD | +23.1% | Beat |
Beat rate: 2/6 (33%) over reported quarters with consensus data.
VKTX valuation and analyst view
| Trailing P/E | -9.01 |
|---|---|
| Trailing EPS | -4.08707 USD |
| Price / book | 8.59 |
| Dividend yield | 0.00% |
| Market cap | 4.30B |
| Analyst consensus | Buy (23 buy / 1 hold / 0 sell) |
| Avg price target | 91.75 USD |
Related research pages
Frequently asked questions
When is Viking Therapeutics (VKTX)'s next earnings date?
Viking Therapeutics is next scheduled to report on 2026-07-29, with a consensus EPS estimate of -1.21 USD.
Did VKTX beat earnings last quarter?
In its 2026-04-29 report, VKTX posted EPS of -1.37 USD versus a -1.01 USD estimate — a miss of 35.6%.
What is VKTX's earnings track record?
Over the last 6 reported quarters with consensus data, VKTX beat estimates 2 times (33%).
What is VKTX's current P/E ratio and EPS?
VKTX trades at a trailing P/E of -9.01 on trailing EPS of -4.087074276616365 USD.
What do analysts rate VKTX?
Analyst consensus is "Buy" across 24 ratings (1 strong buy, 22 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 91.75 USD.